Cost-Effectiveness of Biologic Therapies in Psoriasis Based on a 24-Week Evaluation Study

Abstract

Over a 5 year, each patient on lenalidomide avoided 487 days of transfusion, on average. The incremental cost per life-year without transfusion dependence is USD$14,072 (Exchange Rate= 1USD= 17.55 MXN). According to the sensitivity analysis the model is robust. If all expected patients are treated, their cost would be ~USD$19.7 million, which represents 0.18% of the total budget in the public health sector. ConClusions: Lenalidomide provides important clinical benefits in the treatment of myelodysplastic syndromes with del5q, with a limited economic impact and with a cost per life-year without transfusion with less than 3 times the GDP in Mexico.